13 September 2024
13 September 2024
R&D frameworks are in place for the next pandemic-causing pathogen, but ways to derisk development are unclear.
Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.
The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.
The 340B PATIENTS Act targets limitations on the 340B drug pricing programme to ensure that vulnerable communities can access medications.
Groundbreaking for the Limerick site took place in March 2023, with production expected to commence in 2026.
The vaccine manufacturer said it could also supply 13 million doses by end of 2025 to meet requests by Africa CDC and UNICEF.
Tecentriq Hybreza is the first subcutaneous anti-PD-(L)1 cancer immunotherapy.
Sanofi will pay up to €220m on the achievement of sales-based milestones apart from royalties.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
